Methyldopate

Summary

Methyldopate (CHEMBL1201233) is an approved small-molecule α-adrenergic agonist.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Chemistry: 239.27 Da · C12H17NO4

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1201233
Name	Methyldopate
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	17277
ChEBI	CHEBI:94761
Molecular formula	C12H17NO4
Molecular weight	239.27
InChIKey	SVEBYYWCXTVYCR-LBPRGKRZSA-N

SMILES: CCOC(=O)[C@](C)(CC1=CC(=C(C=C1)O)O)N

IUPAC name: ethyl (2S)-2-amino-3-(3,4-dihydroxyphenyl)-2-methylpropanoate

ChEBI definition: The ethyl ester of α-methyl-L-dopa.

Pharmacological roles (ChEBI): α-adrenergic agonist, antihypertensive agent.

Also known as: Methyldopate, METHYLDOPATE, methyldopate

Parent form; salt/anhydrous children: CHEMBL1200432

Patent coverage: 95 distinct patent families (267 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 260 (97%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indication records carry no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).